Edwards Lifesciences (NYSE:EW) Lowered to Buy Rating by Wall Street Zen

Key Points

• Edwards Lifesciences has been downgraded from a "strong-buy" to a "buy" rating by Wall Street Zen, reflecting a shift in analysts' sentiment regarding the stock's performance.
• The company reported an earnings per share (EPS) of $0.67 for the last quarter, exceeding analysts' expectations and demonstrating a year-over-year revenue increase of 11.9%.
• Despite its rating downgrade, Edwards Lifesciences continues to attract investment interest, with 79.46% of its stock currently owned by institutional investors.

Edwards Lifesciences (NYSE:EW - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued on Saturday.

Several other research analysts have also recently weighed in on the stock. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Barclays lifted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. Wells Fargo & Company lifted their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, August 7th. Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Finally, Evercore ISI lifted their price target on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $86.26.

Edwards Lifesciences Trading Down 0.7%

NYSE:EW opened at $77.50 on Friday. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12 month low of $64.00 and a 12 month high of $83.00. The company has a market cap of $45.50 billion, a PE ratio of 11.15, a price-to-earnings-growth ratio of 3.76 and a beta of 1.07. The company has a 50 day simple moving average of $78.92 and a two-hundred day simple moving average of $75.39.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the firm posted $0.70 EPS. The firm's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts forecast that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,014 shares of company stock worth $1,698,844. 1.29% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

A number of large investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC grew its holdings in Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after purchasing an additional 145 shares during the last quarter. Dynamic Advisor Solutions LLC grew its holdings in Edwards Lifesciences by 2.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock valued at $1,124,000 after purchasing an additional 370 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Edwards Lifesciences by 13.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after purchasing an additional 9,188 shares during the last quarter. United Asset Strategies Inc. grew its holdings in Edwards Lifesciences by 10.4% during the 1st quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company's stock valued at $13,450,000 after purchasing an additional 17,412 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in Edwards Lifesciences by 390.7% during the 1st quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company's stock valued at $633,000 after purchasing an additional 7,013 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.